Sign inJoin waitlistJoin the waitlist

Justin Ortiz

Infectious Disease

Credentials: · · · · ·

History

Pulmonary Disease and Critical Care Medicine
University of Maryland Capital Region Health
2010–2013
Pulmonary Disease and Critical Care Medicine
University of Washington-Seattle Campus
2007–2010
Centers for Disease Control and Prevention
2005–2007
Internal Medicine
University of California-San Francisco
2002–2005
University of California, San Francisco School of Medicine
1998–2002
Colorado State University-Fort Collins
1993–1996

Research

Influenza vaccination of pregnant women and protection of their infants
New England Journal of Medicine · 2014 · 433 citations
Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection
Bulletin of the World Health Organization · 2018 · 248 citations
Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies
Systematic review or meta-analysis · Vaccine · 2017 · 216 citations

Kathleen Neuzil
57 papers
JB
Joseph Bresee
12 papers
NB
Niranjan Bhat
11 papers
Tina Hartert
11 papers
Wilbur Chen
11 papers
DS
David Savitz
10 papers
Christopher Goss
9 papers
Eric Simoes
7 papers
Sarah Williams
7 papers
Kathryn Edwards
5 papers
Ruth Karron
5 papers
Adriana Weinberg
4 papers

Grants

Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB)
NIH Office of the Director · N01
Contact PI · $2.7M · Seattle Children's Hospital
2019–2026
Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation for a Phase II Therapeutic Trial for Trichuris Trichiura
National Institute of Allergy and Infectious Diseases · N01
Contact PI · $20.9K · University of Iowa
2019–2024
Addressing Unanticipated Events for Intranasal Influenza H5 Vaccine Trial
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $1.8M · University of Maryland Baltimore
2020–2024

Clinical trials

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Principal investigator · Completed · Phase 1
Vaccine Company, Inc.
2023–2024
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
Principal investigator · Completed · Phase 1
BlueWillow Biologics
2022–2023